Scarica l'app Stockscreener
17.59
1.79%
0.31
Dopo l'orario di chiusura:
17.20
-0.39
-2.22%
Precedente Chiudi:
$17.28
Aprire:
$16.86
Volume 24 ore:
340.63K
Relative Volume:
2.55
Capitalizzazione di mercato:
$658.22M
Reddito:
$239.40M
Utile/perdita netta:
$104.44M
Rapporto P/E:
-6.8178
EPS:
-2.58
Flusso di cassa netto:
$-18.50M
1 W Prestazione:
-0.40%
1M Prestazione:
-1.90%
6M Prestazione:
+21.81%
1 anno Prestazione:
+17.34%
Intervallo 1D:
$16.86
$18.00
Intervallo di 1 settimana:
$16.86
$18.96
Portata 52W:
$11.35
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
Nome
Entrada Therapeutics Inc
Settore
Industria
Telefono
857-305-1825
Indirizzo
ONE DESIGN CENTER PLACE, BOSTON
Confronta TRDA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
17.59 | 658.22M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
| 2024-01-05 | Iniziato | Oppenheimer | Outperform |
| 2023-04-03 | Iniziato | H.C. Wainwright | Buy |
Entrada Therapeutics Inc Borsa (TRDA) Ultime notizie
Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Marketscreener.com
(TRDA) Proactive Strategies - Stock Traders Daily
Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why - MSN
XTX Topco Ltd Takes $634,000 Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Sold by Fmr LLC - MarketBeat
Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St
Entrada Therapeutics (NASDAQ:TRDA) Upgraded at Roth Capital - Defense World
Roth Mkm Begins Coverage on Entrada Therapeutics (NASDAQ:TRDA) - MarketBeat
Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating - Yahoo Finance
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Purchased by Janus Henderson Group PLC - MarketBeat
Jacobs Levy Equity Management Inc. Has $3.23 Million Stock Position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sell Alert: Natarajan Sethuraman Sells Shares of Entrada Therapeutics Inc (TRDA) - GuruFocus.com
Entrada Therapeutics CFO sells shares worth nearly $120,000 By Investing.com - Investing.com Nigeria
Entrada Therapeutics president sells $320,619 in stock By Investing.com - Investing.com Nigeria
Entrada Therapeutics CFO sells shares worth nearly $120,000 - Investing.com India
Entrada Therapeutics president sells $320,619 in stock - Investing.com
Entrada Therapeutics stock hits 52-week high at $20.5 By Investing.com - Investing.com Canada
Massachusetts Financial Services Co. MA Invests $1.11 Million in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why - MSN
(TRDA) Investment Analysis and Advice - Stock Traders Daily
Connor Clark & Lunn Investment Management Ltd. Has $2.22 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Los Angeles Capital Management LLC Makes New $542,000 Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA) - MarketBeat
Insider Sale at Entrada Therapeutics Inc (TRDA) by President of Research & Development - GuruFocus.com
500: Something went wrong - Investing.com UK
Entrada Therapeutics stock hits 52-week high at $20.28 By Investing.com - Investing.com Canada
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates - MSN
HC Wainwright Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - Defense World
HC Wainwright Analysts Boost Earnings Estimates for TRDA - MarketBeat
Entrada Therapeutics (NASDAQ:TRDA) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Entrada Therapeutics president sells shares worth $339,280 By Investing.com - Investing.com Australia
Equities Analysts Issue Forecasts for TRDA FY2024 Earnings - MarketBeat
HC Wainwright Has Positive Outlook of TRDA FY2024 Earnings - MarketBeat
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock - Benzinga
Oppenheimer Issues Positive Forecast for Entrada Therapeutics (NASDAQ:TRDA) Stock Price - MarketBeat
Entrada Therapeutics stock target increased on positive trial data By Investing.com - Investing.com UK
Entrada Therapeutics (NASDAQ:TRDA) Price Target Raised to $20.00 - MarketBeat
Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Entrada Therapeutics’ Q3 2024 Financial Highlights - TipRanks
Entrada Therapeutics (NASDAQ:TRDA) Hits New 12-Month HighHere's What Happened - MarketBeat
Entrada Therapeutics stock hits 52-week high at $18.22 By Investing.com - Investing.com UK
Entrada Therapeutics : Corporate Presentation - Marketscreener.com
Entrada Therapeutics Reports Third Quarter 2024 Financial Results - The Manila Times
Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going - MSN
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Short Interest Down 19.1% in October - MarketBeat
Short Interest in Entrada Therapeutics, Inc. (NASDAQ:TRDA) Declines By 19.1% - Defense World
Here's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price Strength - MSN
Entrada Therapeutics president sells $10,800 in stock By Investing.com - Investing.com Australia
Natarajan Sethuraman Sells 600 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock - MarketBeat
Entrada Therapeutics Inc Azioni (TRDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Entrada Therapeutics Inc Azioni (TRDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| MPM BIOVENTURES 2018, L.P. | 10% Owner |
Dec 11 '24 |
Sale |
20.23 |
21,787 |
440,751 |
4,381,062 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Dec 10 '24 |
Sale |
20.77 |
22,935 |
476,360 |
4,402,849 |
| MPM BioVentures 2014, L.P. | 10% Owner |
Dec 11 '24 |
Sale |
20.23 |
21,787 |
440,751 |
4,381,062 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Dec 02 '24 |
Option Exercise |
2.10 |
5,000 |
10,500 |
78,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Nov 29 '24 |
Option Exercise |
2.10 |
1,000 |
2,100 |
74,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Dec 02 '24 |
Sale |
20.00 |
5,000 |
99,978 |
73,849 |
| WENTWORTH KORY JAMES | Chief Financial Officer |
Nov 29 '24 |
Sale |
19.97 |
1,000 |
19,970 |
73,849 |
| Sethuraman Natarajan | President, Research & Develop. |
Dec 03 '24 |
Sale |
20.15 |
11,703 |
235,786 |
144,997 |
| Sethuraman Natarajan | President, Research & Develop. |
Dec 02 '24 |
Sale |
20.26 |
4,088 |
82,834 |
156,700 |
| Sethuraman Natarajan | President, Research & Develop. |
Nov 29 '24 |
Sale |
20.00 |
100 |
2,000 |
160,788 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):